Novo Nordisk Annual Report 2021
Contents
Introducing Novo Nordisk Strategic Aspirations
Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021
85
Statement of
Environmental,
Social and
Governance (ESG)
performance
for the year ended 31 December
Environmental performance
Resources
Energy consumption for operations (1,000 GJ)
Share of renewable power for production sites
Water consumption for production sites (1,000 m³)
Breaches of environmental regulatory limit values
Emissions and waste
CO₂ emissions from operations and transportation (1,000 tonnes)
Waste from production sites (1,000 tonnes)
Social performance
Patients
Patients reached with Novo Nordisk's Diabetes care products (estimate in millions)
- Hereof reached via the Novo Nordisk Access to Insulin Commitment (estimate in millions)
- Hereof children reached through the Changing Diabetes in Children programme (cumulative)
People & employees
Employees (total)
Employee turnover
Sustainable employer score²
Frequency of occupational accidents (number per million working hours)
Gender in leadership positions (ratio men:women)
Gender in senior leadership positions (ratio men:women)
Gender in the Board of Directors (ratio men:women)
Societies
Total tax contribution (DKK million)
Donations and other contributions (DKK million).
Governance performance
Governing processes
Business ethics reviews
Relevant employees trained in business ethics
Supplier audits
Product recalls
Failed inspections
Values & trust
Note
2021
2020
2019
7.1
3,387
3,191
2,993
223
7.1
100%
100%
76%
7.2
3,488
3,368
3,149
7.3
12
15
16
7.4
174
170
306
7.5
181
141
124
8.1
34.6
32.8
30.0
8.1.
1.7
3.2
2.9
8.1
31,846
28,296
25,695
8.2
8.2
22
48,478
45,323
43,258
11.0%
7.9%
11.4%
8.3
84%
N/A
N/A
8.4
1.3
1.3
2.2
8.5
57:43
59:41
60:40
8.5
64:36
65:35
67:33
8.5
67:33
62:38
62:38
8.6
16 9
8.7
32,593
92
26,376
158
27,527
105
9.1
37
32
34
9.1
98%
99%
99%
9.2
253
177
236
9.3
1
4
9.4
Facilitations of the Novo Nordisk Way (total)
Company reputation (scale 0-100)³
Animals purchased for research
969
9.5
9.6
567
34
26
32
82.6
N/A
N/A
9.7
47,879
50,036
49,637
1. During 2020, the ceiling price was lowered from USD 4 to USD 3 which affects the comparability of 2021 and prior years.
2. In 2021, the engagement survey was entirely redesigned to support Novo Nordisk's strategic goals. As a result, comparison to previous surveys is not appropriate.
3. Company reputation replaces Company trust in order to capture more dimensions of how Novo Nordisk is perceived by external stakeholders.View entire presentation